Man Group plc Acquires New Stake in Teladoc Health, Inc. $TDOC

Man Group plc acquired a new position in shares of Teladoc Health, Inc. (NYSE:TDOC) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 811,385 shares of the health services provider’s stock, valued at approximately $6,881,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Teladoc Health by 2.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock worth $1,542,000 after purchasing an additional 5,235 shares during the period. NewEdge Advisors LLC lifted its stake in Teladoc Health by 1,278.7% in the first quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock valued at $90,000 after buying an additional 10,485 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Teladoc Health by 5.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock valued at $3,566,000 after buying an additional 24,124 shares during the period. Acadian Asset Management LLC bought a new position in shares of Teladoc Health during the 1st quarter worth approximately $615,000. Finally, Envestnet Asset Management Inc. bought a new position in shares of Teladoc Health during the 2nd quarter worth approximately $89,000. 76.82% of the stock is owned by institutional investors and hedge funds.

Teladoc Health Price Performance

Shares of NYSE:TDOC opened at $6.51 on Friday. The company has a market capitalization of $1.18 billion, a PE ratio of -6.58 and a beta of 2.12. The business has a fifty day moving average price of $7.94 and a two-hundred day moving average price of $6.64. Teladoc Health, Inc. has a 1 year low of $4.40 and a 1 year high of $9.89.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The firm had revenue of $606.93 million during the quarter, compared to the consensus estimate of $615.44 million. During the same period in the prior year, the firm earned ($0.19) EPS. The company’s revenue was down 4.0% compared to the same quarter last year. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Sell-side analysts anticipate that Teladoc Health, Inc. will post -0.89 earnings per share for the current year.

Insider Activity

In other news, insider Fernando M. Rodrigues sold 5,677 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $43,315.51. Following the completion of the sale, the insider directly owned 9,572 shares in the company, valued at approximately $73,034.36. The trade was a 37.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $145,977.16. Following the completion of the sale, the chief executive officer owned 389,894 shares of the company’s stock, valued at $2,974,891.22. The trade was a 4.68% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 39,195 shares of company stock valued at $299,058. Corporate insiders own 0.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on TDOC. Weiss Ratings reissued a “sell (d-)” rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Bank of America boosted their target price on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Citigroup dropped their price target on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research note on Monday, August 3rd. Finally, Canaccord Genuity Group cut their price target on Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $7.54.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.